Consistently, pharmacological inhibition of KCa3.1 decreased inflammatory bowel disease mice symptoms via increasing IL-10 production in Treg cells, suggests that KCa3.1 is responsible for the invalidation of anti-inflammatory efficiency of Treg cells in chronic inflammatory disorders (81, 82). Here, KCNN4 is linked to inflammatory bowel disease.